Cornerstone Capital Management Holdings LLC. grew its position in Eli Lilly and Co (NYSE:LLY) by 19.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 475,127 shares of the company’s stock after purchasing an additional 77,511 shares during the quarter. Cornerstone Capital Management Holdings LLC.’s holdings in Eli Lilly and were worth $40,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gradient Investments LLC bought a new position in shares of Eli Lilly and in the fourth quarter worth approximately $103,000. Avestar Capital LLC bought a new position in shares of Eli Lilly and in the fourth quarter worth approximately $100,000. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and in the second quarter worth approximately $128,000. San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and in the second quarter worth approximately $129,000. Finally, Willingdon Wealth Management bought a new position in shares of Eli Lilly and in the third quarter worth approximately $138,000. Institutional investors and hedge funds own 77.58% of the company’s stock.
A number of equities analysts have weighed in on the stock. Goldman Sachs Group lowered shares of Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price target for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 12th. Finally, Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $93.47.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. Eli Lilly and’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.95 earnings per share. equities analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
In related news, insider Donald A. Zakrowski sold 860 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 212,261 shares of company stock worth $18,627,485. 0.20% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Co (LLY) Holdings Boosted by Cornerstone Capital Management Holdings LLC.” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/13/eli-lilly-and-co-lly-holdings-boosted-by-cornerstone-capital-management-holdings-llc.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.